Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-18
2011-10-25
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S238000
Reexamination Certificate
active
08044052
ABSTRACT:
The present invention relates to compounds of Formula (I)or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.
REFERENCES:
patent: 3576810 (1971-04-01), Duncan et al.
patent: 4116665 (1978-09-01), Krumkalns
patent: 4730047 (1988-03-01), Boyle
patent: 6271015 (2001-08-01), Gilula et al.
patent: 7678796 (2010-03-01), Wallberg et al.
patent: 7737143 (2010-06-01), Burns et al.
patent: 7750011 (2010-07-01), Peters et al.
patent: 7750151 (2010-07-01), Bilodeau et al.
patent: 2001/0032615 (2001-10-01), Yonezawa et al.
patent: 2002/0091116 (2002-07-01), Zhu et al.
patent: 2003/0036655 (2003-02-01), Bley et al.
patent: 2003/0084948 (2003-05-01), Tanaka et al.
patent: 2004/0034101 (2004-02-01), Rao et al.
patent: 2004/0063726 (2004-04-01), Artman
patent: 2004/0087646 (2004-05-01), Differding et al.
patent: 2004/0186148 (2004-09-01), Shankar et al.
patent: 2004/0204477 (2004-10-01), Moll et al.
patent: 2005/0075345 (2005-04-01), Heymans et al.
patent: 2005/0171099 (2005-08-01), Carson et al.
patent: 2006/0106029 (2006-05-01), Ohkubo et al.
patent: 2006/0167044 (2006-07-01), Arnaiz et al.
patent: 2006/0173184 (2006-08-01), Apodaka et al.
patent: 2007/0004741 (2007-01-01), Apodaca et al.
patent: 2008/0103209 (2008-05-01), Piomelli et al.
patent: 2129374 (1995-06-01), None
patent: 102004045796 (2004-09-01), None
patent: 1227090 (2002-07-01), None
patent: 1308443 (2003-07-01), None
patent: 1655297 (2006-10-01), None
patent: 1813606 (2007-01-01), None
patent: 2065369 (2009-06-01), None
patent: 2442839 (1980-06-01), None
patent: 138405 (1969-01-01), None
patent: 1138405 (1969-01-01), None
patent: 1260886 (1972-01-01), None
patent: 1295447 (1972-11-01), None
patent: 1310235 (1973-03-01), None
patent: 2167407 (1984-11-01), None
patent: WO91/11172 (1991-08-01), None
patent: WO93/12107 (1993-06-01), None
patent: WO94/02518 (1994-02-01), None
patent: WO95/06037 (1995-03-01), None
patent: WO9621648 (1996-07-01), None
patent: WO97/24328 (1997-07-01), None
patent: WO97/28141 (1997-08-01), None
patent: WO98/55148 (1998-02-01), None
patent: WO9856771 (1998-12-01), None
patent: WO99/50262 (1999-10-01), None
patent: WO00/58295 (2000-10-01), None
patent: WO00/59477 (2000-10-01), None
patent: WO01/32615 (2001-05-01), None
patent: WO01/53263 (2001-07-01), None
patent: WO01/58891 (2001-08-01), None
patent: WO01/66543 (2001-09-01), None
patent: WO01/95856 (2001-12-01), None
patent: WO0240466 (2002-05-01), None
patent: WO02062963 (2002-08-01), None
patent: WO03037271 (2003-05-01), None
patent: WO03076400 (2003-09-01), None
patent: WO03/084948 (2003-10-01), None
patent: WO03080060 (2003-10-01), None
patent: WO03/099787 (2003-12-01), None
patent: WO2004/037371 (2004-05-01), None
patent: WO2004/087646 (2004-10-01), None
patent: WO2004/100952 (2004-11-01), None
patent: WO2004/101521 (2004-11-01), None
patent: WO2005/007647 (2005-01-01), None
patent: WO2005/044797 (2005-05-01), None
patent: WO2005/051390 (2005-06-01), None
patent: WO2005/115987 (2005-12-01), None
patent: WO2005/121121 (2005-12-01), None
patent: WO2005115370 (2005-12-01), None
patent: WO2006034341 (2006-03-01), None
patent: WO2006/035303 (2006-04-01), None
patent: WO2006/048248 (2006-05-01), None
patent: WO2006/018280 (2006-06-01), None
patent: WO2006/067401 (2006-06-01), None
patent: WO2006/067531 (2006-06-01), None
patent: WO2006/074025 (2006-07-01), None
patent: WO2006/085196 (2006-08-01), None
patent: WO2006/088075 (2006-08-01), None
patent: WO2006116703 (2006-11-01), None
patent: WO2006/129842 (2006-12-01), None
patent: WO2006/137465 (2006-12-01), None
patent: WO2006129199 (2006-12-01), None
patent: WO2007/003962 (2007-01-01), None
patent: WO2007/005510 (2007-01-01), None
patent: WO2007/023882 (2007-01-01), None
patent: WO2007/027352 (2007-03-01), None
patent: WO2007079180 (2007-07-01), None
patent: WO2007/103456 (2007-09-01), None
patent: WO2008005368 (2008-01-01), None
patent: WO2008020866 (2008-02-01), None
patent: WO2008021625 (2008-02-01), None
patent: WO2008022976 (2008-02-01), None
patent: WO2008024139 (2008-02-01), None
patent: WO2008030752 (2008-03-01), None
patent: WO2008153752 (2008-03-01), None
patent: WO2008042892 (2008-04-01), None
patent: WO2008047229 (2008-04-01), None
patent: WO2008/063300 (2008-05-01), None
patent: WO2008063714 (2008-05-01), None
patent: WO2008075978 (2008-06-01), None
Almarsson & Zaworotko; 2004; Chemical Communication; Crystal engineering of the composition of pharmaceutical phases. ; vol. 17; pp. 1889-1896.
Amuro, et al.; 1990;Isolation and characterization of the two distinct genes for human glutamate dehydrogenase; Biochimica et Biophysica Acta; 1049(2); 216-218.
Amuro, et al.; 1988; Molecular Cloning and Nucleotide Sequence of the cDNA for Human Liver Glutamate Dehydrogenase Precursor; Biochimica Res. Commun.; 152(3); 1395-1400.
Arreaza, et al.; 1997; Deletion of a proline-rich region and a transmembrane domain in fatty acid amide hydrolase1;FEBS Letters; 454; 57-60.
Austen, et al.; 1977; Nocotinamide Adenine Dinucleotide-specific Glutamate Dehydrogenase ofNeurospora; Journal of Biological Chemistry; 252; 22; 8142-8149.
Banner, et al.; 1987; Isolation of a Human Brain cDNA for Glutamate Dehydrogenase; Journal of Neurochemistry; 49; 1; 246-252.
Batra,etal.;1989Ident . . . of Histidyl Peptide labeled by 2-(4-Bromo-2,3-dioxobutylthio) adenosine5′-Mono . . . in an ADP Reg . . . Site of Glut . . . Dehy . . . ;Ar.of Bioch.&Biop.270;1;277-85.
Berge, et al.; 1977; Pharmaceutical Salts; Journal of Pharmaceutical Sciences; 66; 1; 1-19.
Bracey, et al; Structural Adaptations in a membrane Enzyme That Terminates Endocannabinoid Signaling; Science; 298; 1793-1796, 2002.
Collins, F.S.; 2002; Induction of neurite outgrowth by a conditioned-medium factor bound to the culture substratum; PNAS; vol. 99 No. 26; 5210-5213.
Cravatt, et al; 1996; Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides; Letters to Nature; vol. 384; 83-87.
Day, et al.; 1999; Role of Fatty acid Amide Hydrolase in the Transport of Endogenous Cannabinoid Anandamide; Molecular Pharmacology; 59; 1369-1375.
DeBank, et al.; 2005; A spectrophotometric assay for fatty acid amide hydrolase suitable for high-throughput screening; Biochemical Pharmacology; 69; 1187-1193.
Deloukas,et al.;1993;Three Human Glutamate Dehydrogenase Genes(GLUD1,GLUDP2, andGLUDP3) Are Located on Chromosome 10q, but Are Not Closely Physically Linked;Genomics;1;676-681.
Deutsch, et al.; 2002; The fatty acid amide hydrolase (FAAH); Prostaglandins, Leukotrienes ad Essential Fatty Acids; 66;(2&3);201-210.
Falck, et al.; 2001; Bromo-Boronolactonization of Olefins; Journal of Organic Chemistry; 66; 7148-7150.
Fang, et al; 2002; Expression, purification and characterizationof human glutamate dehydrogenase (GDH) allosteric regulatory mutations; Biochemical Journal; 363(Pt.1); 81-87.
Finnin, et al.; 1999; Transdermal Penetration Enhancers: Applications, Limitations and Potential; J. of Pharmaceutical Sciences; 88, 10; 955-958.
Finnin and Morgan; 1999; Transdermal Penetration Enhancers:Applications, Limitations and Potential; Journal of Pharmaceutical Sciences; 88(10); 955-958.
Fujioka,et al.; 2001;Mole . . . characterisation of glutamate dehydrogenase gene defects in Japanese patients w/ congenital hyperinsulinism/hyperammonaemia;E.J.ofHum.Gen.9;931-937.
Giang, et al.; 1997; Molecular characterization of human and mouse fatty acid amide hydrolases; PNAS; 94; 2238-2242.
Giang & Cravatt;1997; Molecular characterization of human and mouse fatty acid amide hydrolases; PNAS; vol. 94; 2238-2242.
Haberland, et al.; 1980; Nicotinamide Adenine dinucleotide-specific Glutamate Dehydrogenase ofNeurospora crassa; Journal of Biological Chemistry; 255; 16; 7984-7992.
Haleblian, J.K.; 1975;Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications; Jou
Fay Lorraine Kathleen
Johnson Douglas S.
Kesten Suzanne Ross
Lazerwith Scott E.
Meyers Marvin Jay
Jaisle Cecilia M
Kispert Jennifer A.
Li Linda S.
Pfizer Inc.
Ronau Robert T.
LandOfFree
Biaryl ether urea compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biaryl ether urea compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biaryl ether urea compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298983